The role of earnings briefings cannot be underestimated.

According to data from the China Association for Public Companies, as of June 30, a total of 4,490 companies listed on the Shanghai, Shenzhen, and Beijing stock exchanges held earnings briefings, representing a briefing rate of approximately 95.43%. Among them, companies included in the CSI 300 Index, A+H share dual-listed companies, central SOE-controlled listed companies, and companies listed on the STAR Market and ChiNext basically all held such briefings. Against the backdrop of ongoing deep reforms in China’s capital market, earnings briefings—integral to listed companies’ investor relations management—have become a vital channel for communication between listed companies and investors. Earnings briefings play a tangible and significant role in protecting investors’ rights and interests, enhancing the quality of listed companies, and ensuring the stable development of the capital market—hence their importance cannot be underestimated. For investors, earnings briefings help support sound decision-making. Compared with listed companies, investors are at an information disadvantage; this asymmetry often leads to misjudgments. This is especially true for retail investors, whose understanding of listed companies typically relies solely on written financial reports—reports whose complexity may exceed their professional capacity. Through earnings briefings, investors gain opportunities to interact directly with senior executives—the “key few”—to clarify doubts, deepen their understanding of the company, and thereby make more rational and accurate investment decisions. For listed companies, earnings briefings serve as a crucial channel for signaling, helping stabilize market expectations. Companies can convey comprehensive and detailed information to investors, explain their financial performance, and articulate future business strategies—thereby preventing misunderstandings, strengthening market recognition, and boosting investor confidence. Meanwhile, through dialogue with investors, companies can gather diverse opinions and suggestions, further refine internal operations, and elevate overall management standards. For the capital market as a whole, earnings briefings foster a corporate culture that respects, protects, and rewards investors—enhancing investors’ sense of fulfillment, which contributes positively to market stability. Simultaneously, they break down information barriers between investors and listed companies, shielding investors from market rumors and encouraging healthy investment concepts—namely, long-term, value-based, and rational investing.

International Top Pharmaceutical Companies Weekly News Digest — July 22–28, 2024

• Gilead Sciences: On July 25, 2024, Gilead announced that its second-quarter 2024 financial results and updated guidance will be released after market close on Thursday, August 8, 2024. At 4:30 p.m. Eastern Time on the same day, Gilead’s management team will host a webcast to discuss the company’s Q2 2024 financial performance. • Eli Lilly and Company: On July 25, 2024, Lilly announced that it will release its second-quarter 2024 financial results on August 8, 2024. The company will also hold a conference call at 10:00 a.m. Eastern Time on that day to provide further details regarding its financial performance. • Novo Nordisk: On July 25, 2024, Novo Nordisk announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending an update to the label for Wegovy® (semaglutide 2.4 mg) to reflect data from the SELECT cardiovascular outcomes trial. These data demonstrate a reduction in major adverse cardiovascular events (MACE)—including cardiovascular death, non-fatal myocardial infarction (heart attack), or non-fatal stroke—in overweight or obese adults (baseline BMI ≥27 kg/m²) with established cardiovascular disease (CVD) but without diabetes. The SELECT trial showed that, when added to standard care, Wegovy reduced the risk of MACE by 20% compared with placebo—a statistically significant reduction. Additionally, SELECT trial results indicate consistent MACE risk reduction over five years across subgroups defined by baseline age, sex, race, ethnicity, BMI, and degree of renal impairment. The precise mechanism underlying this cardiovascular risk reduction remains undetermined but is likely multifactorial. The proposed label update also incorporates SELECT trial data showing a 15% reduction in cardiovascular mortality, a 19% reduction in all-cause mortality, and an 18% reduction in a heart failure composite endpoint—including cardiovascular death, urgent heart failure visits, and heart failure hospitalizations—compared with placebo. Based on CHMP’s positive opinion, Novo Nordisk expects the label update to be implemented within approximately one month. SELECT was a randomized, double-blind, parallel-group, placebo-controlled trial designed to evaluate the efficacy of Wegovy versus placebo as an adjunct to standard of care for preventing MACE in patients with cardiovascular disease who are overweight or obese and have no history of diabetes. Eligible participants were aged ≥45 years and had a BMI ≥27 kg/m², with up to five years of follow-up. The primary objective of the SELECT trial was to demonstrate superiority of Wegovy over placebo in reducing the incidence of three-point MACE—defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Key secondary objectives included comparisons of Wegovy versus placebo on mortality, heart failure, and cardiovascular risk factors—including glucose metabolism, body weight, and renal function. The trial enrolled 17,604 adults across more than 800 study sites in 41 countries.

Balchem Corporation Announces Quarterly Conference Call for Third-Quarter Results

Oct 9, 2026

Balchem Corporation scheduled a conference call for October 23, 2026, to discuss third-quarter financial results. CEO Ted Harris and CFO Martin Bengtsson will host the event, with financial data released prior to market opening.

GlobeNewswire

Balchem Corporation Announces Quarterly Conference Call for Third Quarter 2026 Financial Results on October 23, 2026

Yahoo Finance

2026-07-17

Balchem Corporation to announce Q2FY26 results on July 31

2026-07-23

Balchem Earnings Up Next: Can Specialty Ingredients Sustain Growth?

2026-07-27

Balchem (BCPC) Q2 2026 Preview: EPS Est. $1.43, Reports July 31

2026-07-31

Balchem Corporation Posts Q2 Adjusted EPS of $1.49, Surpassing Estimates